Dosing and Administration | LUTATHERA®

The dosing for LUTATHERA remains the same, regardless of patient type¹

Recommended Treatment Regimen With LUTATHERA¹

Infusion times for treatment with LUTATHERA: start with antiemetics, followed by amino acid solution and finally administration of LUTATHERA

^aAdminister long-acting octreotide 30 mg IM between 4 to 24 hours after each dose of LUTATHERA. Do not administer long-acting octreotide within 4 weeks prior to each subsequent dose of LUTATHERA. The interval between infusions may be extended up to 16 weeks in the case of a dose modification due to an adverse reaction. Permanently discontinue LUTATHERA in patients who experience grade 3/4 hypersensitivity reactions. Please see the Prescribing Information for additional information on dose modifications.¹
^bContinue long-acting octreotide 30 mg IM every 4 weeks after completing LUTATHERA until disease progression or for 18 months following treatment initiation at the discretion of the physician.¹

During treatment, administer long-acting octreotide 30 mg IM between 4 to 24 hours after each dose of LUTATHERA

LUTATHERA dosage should be modified based on hematologic, renal, hepatic, hypersensitivity, or other adverse reactions (see full Prescribing Information)¹
For reduced dose administration instructions, refer to section 2.5 (Preparation and Administration) of the full Prescribing Information¹

The recommended dose for LUTATHERA is 7.4 GBq (200 mCi) every 8 weeks (±1 week) for a total of 4 doses¹

Before each dose of LUTATHERA¹

DO NOT ADMINISTER LONG-ACTING SSAs FOR AT LEAST 4 WEEKS

DO NOT ADMINISTER SHORT-ACTING SSAs FOR AT LEAST 24 HOURS

88% of patients completed all 4 doses of LUTATHERA in NETTER-2 and 77% of patients completed all 4 doses of LUTATHERA in NETTER-1¹

Dose Modifications

Recommended dose modifications of LUTATHERA for adverse reactions¹

Thrombocytopenia¹

Anemia and neutropenia¹

Renal toxicity¹

Hepatotoxicity¹

Hypersensitivity reactions^1,†

Any other adverse reaction^1,‡

^*Grading of severity is defined in the most current National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE).¹
^†Including allergic reaction and anaphylaxis.¹
^‡No dose modification required for hematological toxicities of grade 3 or grade 4 solely due to lymphopenia.¹

Preparing and Administering LUTATHERA

Infusion schedule and procedures

Treatment with LUTATHERA also includes premedications and amino acid infusion.¹

Infusion times for treatment with LUTATHERA: start with antiemetics, followed by amino acid infusion and finally administration of LUTATHERA

Hypersensitivity prophylaxis: Premedicate patients who have had prior grade 1/2 hypersensitivity reactions to LUTATHERA. Do not rechallenge patients who experience grade 3/4 hypersensitivity reactions to LUTATHERA.¹

1. Pretreatment antiemetics

2. Concomitant amino acid IV infusion

3. Administration of LUTATHERA

GBq, gigabecquerel; HCI, hydrogen chloride; IM, intramuscular; IV, intravenous; mCi, millicurie; SSAs, somatostatin analogues.

Refer to the LUTATHERA Prescribing Information for more detailed information on radiation requirements and patient counseling

<Previous: Radiation Safety

Next: Novartis Patient Support^TM >

Amino Acid Solution
Characteristic¹	Specification
L-lysine HCI	Between 18 and 25 g^a
L-arginine HCI	Between 18 and 25 g^b
Volume	1 to 2 L
Osmolality	<1200 mOsmol/kg